The Effects of a Food Supplement, Based on Co-Micronized Palmitoylethanolamide (PEA)–Rutin and Hydroxytyrosol, in Metabolic Syndrome Patients: Preliminary Results
Randomised controlled trialHumansWith rutin and hydroxytyrosol
This study tested palmitoylethanolamide together with rutin and hydroxytyrosol. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Randomised controlled trial
- Subjects
- 19 patients with metabolic syndrome enrolled in a crossover design. 16 completed.
- Dose used in the study
- Two capsules a day, each with 360 mg of co-micronised palmitoylethanolamide-rutin and 15 mg of hydroxytyrosol
- Duration
- 8 weeks on each of supplement and placebo, with a 2-week washout
- What was measured
- Body weight and composition, markers of inflammation, blood pressure, glucose and lipids, quality of life and physical performance
What the authors reported
The trial found:
- Small falls in body weight (86.4 to 85.3 kg), BMI and fat mass, and falls in CRP and ESR, during the supplement phase.
- Fat-free mass, phase angle and body cell mass increased with the supplement compared with placebo.
- The fall in IL-6 was not significant.
- There were no significant differences in waist measurements, blood pressure, fasting glucose, triglycerides or HDL cholesterol.
- No adverse events were reported.
Limits of this study
The authors call these preliminary results from about 30% of the planned sample. 16 patients completed. Many outcomes were measured. The authors declared no conflicts of interest. The funding statement was not visible on the page checked.
Source
PubMed 39940271 · doi:10.3390/nu17030413
Entry checked against the full text at the publisher (MDPI) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.